L. Daniel Browne
2018
In 2018, L. Daniel Browne earned a total compensation of $4.7M as President and Chief Executive Officer at Revance Therapeutics, a 37% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $410,190 |
|---|---|
| Option Awards | $2,858,534 |
| Salary | $565,000 |
| Stock Awards | $823,488 |
| Other | $9,210 |
| Total | $4,666,422 |
Browne received $2.9M in option awards, accounting for 61% of the total pay in 2018.
Browne also received $410.2K in non-equity incentive plan, $565K in salary, $823.5K in stock awards and $9.2K in other compensation.
Rankings
In 2018, L. Daniel Browne's compensation ranked 2,215th out of 14,244 executives tracked by ExecPay. In other words, Browne earned more than 84.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,215 out of 14,244 | 84th |
Division Manufacturing | 809 out of 5,765 | 86th |
Major group Chemicals And Allied Products | 270 out of 2,128 | 87th |
Industry group Drugs | 218 out of 1,817 | 88th |
Industry Pharmaceutical Preparations | 169 out of 1,391 | 88th |
Source: SEC filing on March 25, 2019.
Browne's colleagues
We found six more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2018.
2018
Caryn McDowell
Revance Therapeutics
General Counsel
2018
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
2018
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
2018
Todd Zavodnick
Revance Therapeutics
Former Chief Commercial Officer and President, Aesthetics & Therapeutics
2018
Lauren Silvernail
Revance Therapeutics
Chief Financial Officer
2018
Cyril Allouche
Revance Therapeutics